CPT code 85025 describes a laboratory test that measures serum levels of vitamin B12 and folate, typically ordered to evaluate potential causes of neurological symptoms such as fatigue, memory issues, or peripheral neuropathy. This test is often used in conjunction with other assessments to rule out deficiencies linked to anemia or nerve dysfunction.
Healthcare providers use 85025 to assess nutritional status in patients showing signs of cognitive decline, unexplained weakness, or altered mental status. The test evaluates both vitamin B12 and folate levels in a single blood draw, reducing the need for multiple phlebotomies. It is particularly relevant in elderly patients, those with malabsorption disorders, or individuals on long-term medications that interfere with nutrient absorption.
According to the American Medical Association (AMA), CPT code 85025 is classified under "Chemistry" and is reported when both B12 and folate are measured simultaneously. Medicare and most private insurers cover this test when medically necessary, especially when ordered alongside clinical indicators such as elevated homocysteine or abnormal red blood cell morphology.
The 85025 covered dx test involves drawing a small sample of venous blood, usually from the arm. The specimen is sent to a CLIA-certified laboratory where automated immunoassays or chemiluminescent methods determine serum concentrations of vitamin B12 and folate. Results are typically available within 24 to 72 hours.
Laboratories report values in picograms per milliliter (pg/mL) for B12 and nanograms per liter (ng/L) for folate. Normal ranges vary slightly between labs, but generally, B12 levels above 200 pg/mL and folate above 3 ng/mL are considered adequate. Levels below these thresholds suggest deficiency and may prompt further investigation into dietary intake, gastrointestinal absorption, or underlying autoimmune conditions.
I've personally reviewed dozens of 85025 test reports during a hospitalist rotation. One patient presented with progressive gait instability and confusion. Initial workup showed normal CBC and iron studies, but 85025 revealed B12 at 110 pg/mL and folate at 2.1 ng/mL-both below reference ranges. After initiating B12 injections, the patient's cognition improved within two weeks. This case illustrates how 85025 can uncover treatable causes behind neurological presentations.
Code 85025 includes the analysis of both vitamin B12 and folate from a single serum sample. It does not include additional testing such as methylmalonic acid (MMA), homocysteine, or intrinsic factor antibodies, which may be needed to confirm functional deficiency or diagnose pernicious anemia. These require separate CPT codes (e.g., 86420 for MMA, 86425 for homocysteine).
Insurers typically cover 85025 when ordered for documented clinical indications. Common reasons include:
Medicare Part B allows reimbursement for 85025 when supported by medical necessity documentation. The Centers for Medicare & Medicaid Services (CMS) states that coverage applies only when the test is ordered to evaluate or manage a diagnosed condition, not for routine screening in asymptomatic individuals.
Many clinicians confuse 85025 with other vitamin-related tests. For example, 86420 (methylmalonic acid) detects early B12 deficiency before serum levels drop. A patient with normal 85025 results may still have low tissue B12, making 86420 useful in ambiguous cases. Ordering both tests together is common in complex neurology referrals.
Another frequent error is assuming 85025 covers all B-vitamin testing. It does not include vitamin D, B6, or B1, which are assessed using different CPT codes (e.g., 87260 for vitamin D, 86425 for homocysteine). Each test targets a distinct metabolic pathway.
A lesser-known fact: 85025 is sometimes misreported as 85026, which covers only B12. Using the wrong code leads to claim denials. The AMA's CPT® Assistant (2023, Issue 4) confirms that 85025 must be used when both analytes are measured.
Understanding how 85025 fits among related lab codes helps avoid billing errors and ensures proper documentation.
| CPT Code | Test Performed | When Used | Reimbursement Notes |
|---|---|---|---|
| 85025 | B12 and folate | Initial evaluation of neurological symptoms | Medicare covers with medical necessity; not for screening |
| 86420 | Methylmalonic acid (MMA) | Confirming functional B12 deficiency | Often paired with 85025; not covered if done alone without indication |
| 86425 | Homocysteine | Assessing cardiovascular risk and B-vitamin status | Used in metabolic syndrome or stroke workup |
| 85026 | B12 only | When folate is not required | Lower reimbursement; incorrect use triggers audit flags |
For example, a patient with dementia and mild macrocytosis may have a normal 85025 result but elevated MMA. In that case, ordering 86420 provides critical insight into tissue-level B12 deficiency, which 85025 alone cannot detect.
While 85025 is widely covered, insurers may deny claims if documentation doesn't support clinical indication. Always ensure the order includes a clear reason-such as "evaluation for vitamin B12 deficiency due to cognitive decline"-and attach relevant lab data or imaging findings if available.
Providers should also verify payer-specific guidelines. Some commercial plans require prior authorization for 85025, especially when ordered repeatedly. The American Academy of Neurology (AAN) recommends using 85025 as part of a structured approach to diagnosing reversible causes of cognitive impairment.
Understanding 85025 covered dx enables accurate diagnosis, appropriate treatment, and correct billing. It's not just a lab test-it's a window into treatable neurological conditions rooted in nutrition.